Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Younchul Kim"'
Autor:
Judith D Goldberg, Joseph Markowitz, Jeffrey Weber, Ragini Kudchadkar, Tomas Kirchhoff, Anna Pavlick, Zeynep Eroglu, Melinda Vassallo, David M Woods, Andrew S Brohl, Nikhil I Khushalani, Alison Richards, Younchul Kim, Biwei Cao, Robert Ferguson, Kelsey R Monson, Carol M Amato, Paulo Burke, Ann Strange, Emily Monk, Geoffrey Thomas Gibney
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 11 (2022)
Background Adjuvant therapy for high-risk resected melanoma with programmed cell-death 1 blockade results in a median relapse-free survival (RFS) of 5 years. The addition of low dose ipilimumab (IPI) to a regimen of adjuvant nivolumab (NIVO) in Check
Externí odkaz:
https://doaj.org/article/1c7d034388cd4ebbbabd2100271c621e
Autor:
Yun Song, John F Thompson, Frances A Collichio, Tasha Hughes, John Vetto, Dale Han, Jonathan Zager, Zeynep Eroglu, Jennifer Downs, David E Gyorki, Nikhil I Khushalani, Alexander van Akkooi, Georgia Beasley, Lisa Kottschade, Hidde M Kroon, Ann Lee, Norma E Farrow, Giorgos Karakousis, Michael Lowe, Avinash Sharma, Kristy K Broman, Amanda Nijhuis, Tina J Hieken, Jeffrey M Farma, Meghan Hotz, Jeremiah Deneve, Martin Fleming, Edmund K Bartlett, Lesly Dossett, Russell S Berman, Emma Stahlie, Jane Yuet Ching Hui, Marc Moncrieff, Jenny Nobes, Kirsten Baecher, Matthew Perez, David W Ollila, Roger Olofsson Bagge, Jan Mattsson, Harvey Chai, Jyri Teras, James Sun, Michael J Carr, Ankita Tandon, Nalan Akgul Babacan, Younchul Kim, Mahrukh Naqvi
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 8 (2022)
Until recently, most patients with sentinel lymph node-positive (SLN+) melanoma underwent a completion lymph node dissection (CLND), as mandated in published trials of adjuvant systemic therapies. Following multicenter selective lymphadenectomy trial
Externí odkaz:
https://doaj.org/article/5e2609c2e5e44274aabf900f1ff2c1c7
Autor:
Nikhil I Khushalani, Melinda Vassallo, Judith D Goldberg, Zeynep Eroglu, Younchul Kim, Biwei Cao, Robert Ferguson, Kelsey R Monson, Tomas Kirchhoff, Carol M Amato, Paulo Burke, Ann Strange, Emily Monk, Geoffrey Thomas Gibney, Ragini Kudchadkar, Joseph Markowitz, Andrew S Brohl, Anna Pavlick, Alison Richards, David M Woods, Jeffrey Weber
Publikováno v:
Journal for immunotherapy of cancer. 10(11)
BackgroundAdjuvant therapy for high-risk resected melanoma with programmed cell-death 1 blockade results in a median relapse-free survival (RFS) of 5 years. The addition of low dose ipilimumab (IPI) to a regimen of adjuvant nivolumab (NIVO) in CheckM
Autor:
M. Catherine Lee, Weihong Sun, Christine Laronga, Junmin Whiting, Younchul Kim, Emily L Siegel
Publikováno v:
Breast Cancer Research and Treatment. 188:641-648
Operative complications affect recurrence in non-breast malignancies. Rising rates of mastectomy with immediate reconstruction and their increased post-operative complications fuel concerns for poorer outcome in breast cancer (BC). We sought to deter
Autor:
Zeynep Eroglu, Kristy K Broman, John F Thompson, Amanda Nijhuis, Tina J Hieken, Lisa Kottschade, Jeffrey M Farma, Meghan Hotz, Jeremiah Deneve, Martin Fleming, Edmund K Bartlett, Avinash Sharma, Lesly Dossett, Tasha Hughes, David E Gyorki, Jennifer Downs, Giorgos Karakousis, Yun Song, Ann Lee, Russell S Berman, Alexander van Akkooi, Emma Stahlie, Dale Han, John Vetto, Georgia Beasley, Norma E Farrow, Jane Yuet Ching Hui, Marc Moncrieff, Jenny Nobes, Kirsten Baecher, Matthew Perez, Michael Lowe, David W Ollila, Frances A Collichio, Roger Olofsson Bagge, Jan Mattsson, Hidde M Kroon, Harvey Chai, Jyri Teras, James Sun, Michael J Carr, Ankita Tandon, Nalan Akgul Babacan, Younchul Kim, Mahrukh Naqvi, Jonathan Zager, Nikhil I Khushalani
Publikováno v:
Journal for ImmunoTherapy of Cancer. 10:e004417
Until recently, most patients with sentinel lymph node-positive (SLN+) melanoma underwent a completion lymph node dissection (CLND), as mandated in published trials of adjuvant systemic therapies. Following multicenter selective lymphadenectomy trial